Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, Kohler BA, Jemal A. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–800. https://doi.org/10.1002/cncr.31551.

Article  PubMed  Google Scholar 

Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O’Shaughnessy J. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–7. https://doi.org/10.1200/JCO.2007.11.9362.

Article  PubMed  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8.

Article  CAS  PubMed  Google Scholar 

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward WA. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003.

Article  PubMed  Google Scholar 

Ost P, Jereczek-Fossa BA, As NV, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgo A, Brown L, Tree A, Miralbell R, De Meerleer G. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12. https://doi.org/10.1016/j.eururo.2015.07.004.

Article  PubMed  Google Scholar 

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–8. https://doi.org/10.1200/JCO.20.00818.

Article  PubMed  PubMed Central  Google Scholar 

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–65. https://doi.org/10.1200/JCO.19.00201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115(3):601–8. https://doi.org/10.1007/s10549-008-0157-4.

Article  PubMed  Google Scholar 

Onal C, Guler OC, Yildirim BA. Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast. 2018;42:150–6. https://doi.org/10.1016/j.breast.2018.09.006.

Article  PubMed  Google Scholar 

Niibe Y, Nishimura T, Inoue T, Karasawa K, Shioyama Y, Jingu K, Shirato H. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects. BMC Cancer. 2016;16(1):659. https://doi.org/10.1186/s12885-016-2680-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamashita H, Niibe Y, Yamamoto T, Katsui K, Jingu K, Kanazawa S, Terahara A, Nakagawa K. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligometastases. Jpn J Clin Oncol. 2016;46(7):687–91. https://doi.org/10.1093/jjco/hyw047.

Article  PubMed  PubMed Central  Google Scholar 

Patel PH, Palma D, McDonald F, Tree AC. The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively? Clin Oncol (R Coll Radiol). 2019;31(12):824–33. https://doi.org/10.1016/j.clon.2019.05.015.

Article  CAS  PubMed  Google Scholar 

Huang F, Wu G, Yang K. Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol. 2014;9:230. https://doi.org/10.1186/s13014-014-0230-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel PR, Yoo DS, Niibe Y, Urbanic JJ, Salama JK. A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulm Med. 2012;2012: 480961. https://doi.org/10.1155/2012/480961.

Article  PubMed  PubMed Central  Google Scholar 

Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016;89(1066):20160251. https://doi.org/10.1259/bjr.20160251.

Article  PubMed  PubMed Central  Google Scholar 

Mitchell KG, Farooqi A, Ludmir EB, Corsini EM, Zhang J, Sepesi B, Vaporciyan AA, Swisher SG, Heymach JV, Zhang J, Gomez DR, Antonoff MB. Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2020;21(1):37–46.e7. https://doi.org/10.1016/j.cllc.2019.07.007.

Article  PubMed  Google Scholar 

Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, Tai KH, Udovicich C, Lim A, Selbie L, Hofman MS, Kron T, Moon D, Goad J, Lawrentschuk N, Foroudi F. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62. https://doi.org/10.1016/j.eururo.2018.06.004.

Article  PubMed  Google Scholar 

Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, Franceschini D, Navarria P, Reggiori G, Tomatis S, Scorsetti M. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. 2019;133:220–6. https://doi.org/10.1016/j.radonc.2018.10.024.

Article  PubMed  Google Scholar 

Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016;122(14):2242–50. https://doi.org/10.1002/cncr.30058.

Article  CAS  PubMed  Google Scholar 

Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, Nogi H, Kawase K, Takeyama H, Toriumi Y, Uchida K, Kobayashi M, Kanehira C, Suzuki M, Ando N, Natori K, Kuraishi Y. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer. 2012;19(3):218–37. https://doi.org/10.1007/s12282-012-0347-0.

Article  PubMed  Google Scholar 

David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, Loi S, Siva S. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast. 2020;49:55–62. https://doi.org/10.1016/j.breast.2019.10.016.

Article  PubMed  Google Scholar 

Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M. Radical radiation therapy for oligometastatic breast cancer: results of a prospective phase II trial. Radiother Oncol. 2018;126(1):177–80. https://doi.org/10.1016/j.radonc.2017.08.032.

Article  PubMed  Google Scholar 

Weykamp F, König L, Seidensaal K, Forster T, Hoegen P, Akbaba S, Mende S, Welte SE, Deutsch TM, Schneeweiss A, Debus J, Hörner-Rieber J. Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol. 2020;10:987. https://doi.org/10.3389/fonc.2020.00987.

Article  PubMed  PubMed Central  Google Scholar 

Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, Navarria P, D’Agostino GR, Masci G, Torrisi R, Testori A, Tinterri C, Santoro A. Stereotactic body radiation therapy: a promising chance for oligometastatic breast cancer. Breast. 2016;26:11–7. https://doi.org/10.1016/j.breast.2015.12.002.

Article  PubMed  Google Scholar 

Yoo GS, Yu JI, Park W, Huh SJ, Choi DH. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J. 2015;33(4):301–9. https://doi.org/10.3857/roj.2015.33.4.301.

Article  PubMed  PubMed Central  Google Scholar 

Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN, CURB Study Group. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403(10422):171–82. https://doi.org/10.1016/S0140-6736(23)01857-3.

Article  PubMed